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Introduction: A cluster of three related cases of tuberculosis (TB) with primary multidrug
resistance was investigated at the Centre Hospitalier Universitaire of Kigali (CHUK) in Rwanda.
The patients were HIV-1/2 seronegative. Patients 1 and 2 were hospitalized in the same room of
CHUK for one month. Patient 3 was a younger sibling of patient 2.
Methods: Drug susceptibility of two consecutive Mycobacterium tuberculosis isolates from each
patient was tested by the BACTEC 460 radiometric method. DNA fingerprinting was performed
using spoligotyping and mycobacterial interspersed repetitive units of variable numbers of
tandem repeats (MIRU-VNTR) analysis. All patients initially received the World Health Organiza-
tion category I regimen.
Results: The isolates collected during the first TB episode were resistant to isoniazid, rifampin
and ethambutol. After subsequent retreatment regimens with rifampin, isoniazid, streptomycin,
pyrazinamide (8 months) and rifampin, isoniazid, streptomycin, pyrazinamide, ciprofloxacin (21
months), patients 1 and 2 developed additional resistance to streptomycin and quinolones.
Patient 3 received only the category I regimen and consecutive isolates retained the initial drug
susceptibility pattern. All isolates were genetically indistinguishable by spoligotyping and MIRU-
VNTR, indicating the same origin.
Conclusions: These observations highlight the risk of nosocomial transmission of multidrug-
resistant (MDR) TB and the possible selection of secondary resistance to second-line drugs if a
single new drug is added at the time of retreatment of MDR TB patients.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.§ Presented at the 36th Union Conference on Lung Health, Paris, France, 18—22 October 2005 (Abstract PS-1252-20).
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Tuberculosis (TB) caused by bacteria belonging to the Myco-
bacterium tuberculosis complex, is one of the leading infec-
tiousdiseasesworldwide.People in contactwith contagiousTB
patients are at risk of infection, and may even develop active
disease faster when they are frequently in close contact with
the contagious source because of the high bacillary load
transmitted.1—3 The detection of sources of infection implies
discrimination between strains of M. tuberculosis.4—6 The
development of DNA-fingerprinting tools in the last two dec-
ades has considerably improved the capacity to distinguishM.
tuberculosis strains, thereby enabling tracking of strains in the
community, and has made the designing of prevention and
control strategies to block further transmission possible.7—9
These tools include the insertion sequence IS6110-based
restriction fragment length polymorphism (IS6110-RFLP), spo-
ligotyping, and more recently, typing based on variable num-
bers of tandem repeats (VNTRs) ofmycobacterial interspersed
repetitiveunits (MIRU-VNTR).10—14 The lattermethods have an
advantage over IS6110-RFLP because they are less labor inten-
sive, involve an amplification step that requires very little
DNA, and can be easily interpreted.15—17
Another phenomenon to be considered in the assessment
of the clinical effectiveness of a treatment regimen in resis-
tant TB is termed the ‘amplifier effect of short-course che-
motherapy’.18 This term describes the process by which
patients infected with strains resistant to at least one drug
not only fail short-course chemotherapy (SCC), but in the
process may recruit additional resistance to other drugs.19
We report herein an example of a ‘case-contact’ transmis-
sion of TB using DNA fingerprinting analyses, and demonstrate
the ‘amplifier effect’ of drug resistance in multidrug-resis-
tant (MDR) TB retreatment patients.
Patient histories
Patient 1
A 23-year-old female was diagnosed with TB by smear micro-









1 23/F Negative No 01/2001 7/2001
(TB disease)
2 22/F Negative No 09/2002 7/2001
(malaria)
3 16/F Negative No* 09/2003 7/2001
(care of sister)
F, female; MIRU-VNTR, mycobacterial interspersed repetitive units of
(Spoligotype data shown are presented in binary format recently prop
* Case contact: Yes.(Table 1). She was HIV-1/2 seronegative, had no family ties
with patients 2 and 3, but was hospitalized for 1 month in the
same room as patient 2 during the first treatment phase of
category II (2(SERHZ)7/1(ERHZ)7/5(ERH)3) (July 2001). She
received the World Health Organization (WHO) category I
treatment regimen (2(ERHZ)7/4(RH)3) but remained smear
positive after 5 months after which the patient was retreated
with a category II regimen (Table 2). In March 2002, the
patient received the same retreatment regimen with the
addition of ciprofloxacin.
Patient 2
This female, aged 22 years, was first hospitalized in July 2001
at Gikondo Health Center, in the same room as patient 2, for
malaria (Table 1). She was later diagnosed with TB by smear
microscopy (new case) in September 2002 at the Centre
Hospitalier Universitaire of Kigali (CHUK) and was seronega-
tive for HIV-1/2. She was transferred to Gikondo Health
Center where she begun treatment with the category I regi-
men. However, the patient remained smear positive after 5
months of treatment, and was started on the category II
regimen in March 2003; she was hospitalized several times
(Table 2). Three months after starting the category II treat-
ment (June 2003), the patient was confirmed to be an MDR
case, with the isolate being resistant to isoniazid (H), rifam-
pin (R), ethambutol (E) and rifabutin. She began another
retreatment with streptomycin (S), isoniazid, ofloxacin and
clofazimine, but this patient remained smear positive in
November, and her treatment was consequently changed
to second-line drugs (clofazimine, ofloxacin, prothionamide
and pyrazinamide). However, the patient died four months
later.
Patient 3
Patient 3 was a younger sibling of patient 2. She was
16 years old and seronegative for HIV-1/2 (Table 1). She
took care of her sister while in hospital and later accom-
panied her to receive treatment from a DOT center. In
September 2003, she was diagnosed with TB (new case)







02/2001 A1 223325153423 777777777760731
10/2003 B1 223325153423 777777777760731
09/2002 A2 223325153423 777777777760731
11/2003 B2 223325153423 777777777760731
09/2003 A3 223325153423 777777777760731
02/2004 B3 223325153423 777777777760731
variable numbers of tandem repeats.
osed by Filliol I, et al. Emerg Infect Dis 2002;11:1347—9.)
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Outcome Retreatment Cat I
or Cat II + Cpx/Ofx




1 HRE-(r) + Ofx-(s) HREZ Failure HREZS (8 months)
HREZS + Cpx
(21 months)
Failure HRES/Cpx + Ofx-(r) MDR ongoing
2 HRE-(r) + Ofx-(s) HREZ Failure HREZS (3 months)
HS + Ofx + Cfz
(21months)
Failure HRES/Cpx + Ofx-(r) Died after
4 months
3 HRE-(r) + Ofx-(s) HREZ Failure HREZ Failure HRE-(r) + Ofx-(s) MDR ongoing
(s), susceptible; (r), resistant; H, isoniazid; R, rifampin; E, ethambutol; Z, pyrazinamide; S, streptomycin; Cpx, ciprofloxacin; Ofx, ofloxacin;
Cfz, clofazimine.regimen. However, the patient remained smear positive
after three months of treatment. The M. tuberculosis
isolate cultured from this patient was found to be resistant
to isoniazid, rifampin, ethambutol and rifabutin like the
one initially cultured from her older sister after the first
regimen. In April 2004, she was transferred to France




A sputum sample was collected for culture from each
patient before or within the first two weeks of treatment
during the first and second TB episodes. The samples were
mixed with 1% cetylpyridinium chloride (CPC) and shipped
to the national reference laboratory (LRN) of Kigali for
analysis. Upon receipt at the LRN, each sample was cul-
tured on Lo¨wenstein—Jensen medium and Coletsos after
decontamination using the Petroff procedure.20 Primary
cultures that resembled M. tuberculosis were sent to the
Mycobacteriology Unit at the Saint Pierre Hospital labora-
tory, Brussels for species identification and drug suscept-
ibility testing (DST), and to the Mycobacteriology Unit,
Institute of Tropical Medicine, Antwerp for fingerprinting.
Primary cultures were identified by classical methods and
DST was performed with rifampin (2 mg/ml), isoniazid
(0.2 mg/ml), streptomycin (4 mg/ml) and ethambutol
(5 mg/ml) using the BACTEC 460 radiometric method as
described by Siddiqi et al.21—23
Phenotypic susceptibility testing for pyrazinamide was not
performed, because the results of this test can be difficult to
reproduce and may not correlate well with drug suscept-
ibility in vivo.24,25 All MDR strains were further subjected to
second-line antituberculosis drug testing at the Saint Pierre
Hospital laboratory, Brussels. The drugs tested included
ethionamide (20 mg/ml), ofloxacin (2 mg/ml), ciprofloxacin
(2 mg/ml), amikacin (10 mg/ml), kanamycin (20 mg/ml) and
rifabutin (1 mg/ml).22,23
Quality control was established by comparing the results
of DST performed at Saint Pierre and the Pasteur Institute,
Paris, and these were 100% concordant. This study was
approved by the Ethics Review Board at the Centre Hospita-
lier Universitaire de Kigali (CHUK).HIV testing
The HIV status was tested using two enzyme-linked immu-
nosorbent assays (ELISA): Vironostika HIV Uni-form II (bioMer-
ieux, Marcy l’e´toile, France) and Murex HIV 1.2.0 (Abbott
Murex, IL, USA).
DNA extraction
The genomic DNA used for PCR analysis was obtained by
resuspending mycobacterial colonies into 200 ml in 1 TE
(10 mM Tris-HCl, 1 mM EDTA (pH 8.0)) followed by boiling for
5 min in a water bath.
Spoligotyping
Spoligotyping was performed with a commercial kit (Isogen
Bioscience BV, Maarssen, The Netherlands) by the previously
described method.10 Briefly, 4 ml of the heat-killed bacterial
suspension from each sample was used for amplification of the
direct-repeat (DR) region with oligonucleotides DRa (50 bioti-
nylated) and DRb. The labeled amplicons were used as probes
for hybridizationwith a set of 43 knownoligonucleotide spacer
sequences of M. tuberculosis H37Rv and M. bovis BCG P3
covalently bound to a nylon membrane (Amersham Bios-
ciences, Little Chalfont, UK). Bound PCR fragments were
detectedwithastreptavidinhorseradishperoxidase-enhanced
conjugate and an enhanced chemiluminescence system, fol-
lowed by exposure to ECL hyperfilm (Amersham Pharmacia-
Biotech, Roosendael, The Netherlands). The spoligotyping
patterns were compared using Excel computer software.
MIRU-VNTR analysis
PCRs were carried out by using the Hot Start Taq DNA poly-
merase kit (Qiagen, Hilden, Germany), as described else-
where.12 The PCR fragments were analyzed by agarose gel
electrophoresis using 3% NuSieve agarose (Cambrex Bios-
ciences, USA). The sizes of the amplicons were estimated
using a Gene RulerTM 100-bp ladder (MBI Fermentas).
Results and discussion
All initial M. tuberculosis isolates collected from the three
patients had identical fingerprints by spoligotyping and
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patients shared a common source of infection. Given the fact
that none of these patients had a past history of TB, or cases
of active TB in their direct environment, and that patients 1
and 2 shared the same room for more than one month during
the infective stage of patient 1 (smear positive), it is most
likely that the MDR M. tuberculosis strain was transmitted in
the hospital from patient 1 to patient 2. From the data we
obtained, the initial source of infection for patient 1 is
probably the mother who died of TB/HIV co-infection two
years earlier. It is not clear whether patient 3 was infected by
patient 1 while taking care of her sister (July 2001) or later by
her sister when she developed active TB (September 2002).
The fact that initial and subsequent M. tuberculosis isolates
showed identical fingerprints clearly demonstrates treat-
ment failure in all three cases.
None of the patients hospitalized in the same room with
patients 1 and 2 developed TB. In addition, no other family
member developed TB except for the younger sister of
patient 2 who took care of her while in hospital.
During the first phase of treatment, the three patients’
isolates had the same MDR profile to the first-line drugs
tested and were all susceptible to streptomycin and the
second-line drugs, ofloxacin and kanamycin (Table 2).
Although we do not have intermediate M. tuberculosis iso-
lates after retreatment with category II, and the resistance
profile to pyrazinamide was not determined, the final drug-
resistance profiles suggest that patients 1 and 2 probably
independently developed resistance to streptomycin during
retreatment with category II, since in fact streptomycin was
added as a single new drug to the four drugs, for which
resistance already existed to at least three (isoniazid, rifam-
pin, ethambutol). After receiving 8 months of category II
retreatment, and meanwhile probable acquisition of resis-
tance to streptomycin, ciprofloxacin was added for retreat-
ment of patient 1 and therefore de facto could be considered
as monotherapy. The strain finally became resistant to cipro-
floxacin and ofloxacin (Table 2). Cross-resistance between
fluoroquinolones is a well-known phenomenon.3 On the other
hand, for patient 2, ofloxacin and clofazimine were added to
streptomycin and isoniazid after three months of the cate-
gory II treatment regimen that failed. The strain developed
resistance to ofloxacin and ciprofloxacin, but remained sus-
ceptible to clofazimine. This drug has been used for leprosy
and has excellent in vitro inhibitory activity against M.
tuberculosis, but there is little or no information on its in
vivo activity.26,27 It was demonstrated in vitro that clofazi-
mine in combination with isoniazid may result in synergistic
activity against M. tuberculosis.28 This synergistic activity,
however, may be more pronounced against the wild-type M.
tuberculosis strain than against strains harboring the katG
S315T mutation.28 Since our isolate was already resistant to
isoniazid, it is likely that clofazimine had no synergistic
activity on the isolate. The additional resistance to strepto-
mycin results from the ‘amplifier effect’.29,30
This phenomenon in which additional resistance to anti-
tuberculosis drugs is observed among polyresistant patients
who receive the standard SCC regimen has previously been
described, but its frequency is not well known.29
In a recent study, Quy et al. showed the limitations of the
(2(SERHZ)7/6(HE)7) in preventing the amplification effect in
patients with primary resistance even other than MDR TB,including single drug resistance. In their report the authors
suggest that replacing streptomycin in the standard regimen
and/or adding a third drug to the continuation phase may be
one possible way of breaking the amplification jugger-
naut.30,31
The acquired resistance to the quinolones clearly showed
that second-line drugs should never be administrated as a
single new drug, but rather be part of a complete MDR TB
treatment regimen including at least three drugs that have
not been used before.30
These alarming findings on the prevalence of resistance to
second-line drugs, especially among MDR TB patients, high-
light the risk of producing primary resistance to fluoroqui-
nolones, creating incurable TB strains and jeopardizing the
potential of fluoroquinolones to become part of first-line
anti-TB drug therapy in directly observed treatment short-
course (DOTS)-plus. The present study confirms that indivi-
duals who are in frequent contact with contagious TB
patients have a high risk of contracting TB and progressing
to active disease. Nosocomial transmission ofM. tuberculosis
in treatment failures constitutes a real risk. Although the
sample size of our data is small to draw definitive conclu-
sions, our report nonetheless indicates the potential risk of
producing resistance to additional drugs if patients infected
with polyresistant M. tuberculosis strains receive the stan-
dard SCC andwhen a single drug (e.g. a quinolone) is added to
a failed treatment regime, confirming the transmission of
MDR strains in three cases.
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